个人简历

张小博，男，副教授，硕士生导师，西北农林科技大学与美国田纳西大学联合培养博士，2013年底获理学博士，2014年入职中国药科大学。主要从事天然产物及非甾体抗炎药物肿瘤药理学研究及抗肿瘤创新药物开发的工作。主要研究方向包括：肝癌体内外模型建立及天然药物干预机制研究、TGFβ家族成员参与肿瘤发生发展的分子机制及基于此的药物开发。近年来，以第一作者或共同第一作者发表多篇SCI收录论文，主持国家自然科学基金（81503098）、中央高校基本科研业务费项目（2015PY013）各1项，参与多项国家级省部级课题及抗肿瘤新药的研发工作。

研究领域

肝癌体内外模型建立及天然药物干预机制研究、TGFβ家族成员参与肿瘤发生发展的分子机制及基于此的药物开发

近期论文

Zhang X, Liu Y, Lu L, Huang S, Ding Y, Zhang Y, Guo Q, Li Z, Zhao L. Oroxyloside A Overcomes Bone Marrow Microenvironment-Mediated Chronic Myelogenous Leukemia Resistance to Imatinib via Suppressing Hedgehog Pathway. Front Pharmacol. 2017, 8:526.
Zhang X, Kang Y, Huo T, Tao R, Wang X, Li Z, Guo Q, Zhao L. GL-V9 induced upregulation and mitochondrial localization of NAG-1 associates with ROS generation and cell death in hepatocellular carcinoma cells. Free Radic Biol Med. 2017, 112:49-59.
Xu X, Zhang X, Zhang Y, Yang L, Liu Y, Huang S, Lu L, Kong L, Li Z, Guo Q, Zhao L. Wogonin reversed resistant human myelogenous leukemia cells via inhibiting Nrf2 signaling by Stat3/NF-κB inactivation. Sci Rep. 2017, 7: 39950 (co-first author)
Zhang X, Sukamporn P, Zhang S, Min KW, Baek SJ. 3,3'-diindolylmethane downregulates cyclin D1 through triggering endoplasmic reticulum stress in colorectal cancer cells. Oncol Rep. 2017, 38(1): 569-574.
Zhang X, Min KW, Liggett JL, Baek SJ. Disruption of the transforming growth factor-β (TGF-β) pathway by tolfenamic acid via the ERK MAP kinase pathway. Carcinogenesis. 2013, 34(12): 2900-2907.
Zhang X, Lee SH, Min KW, McEntee MF, Jeong JB, Li Q, Baek SJ. The involvement of endoplasmic reticulum stress in the suppression of colorectal tumorigenesis by tolfenamic acid. Cancer Prev Res (Phila). 2013, 6(12): 1337-1347.
Zhang X, Min KW, Wimalasena J, Baek SJ. Cyclin D1 degradation and p21 induction contribute to growth inhibition of colorectal cancer cells induced by epigallocatechin-3-gallate. J Cancer Res Clin Oncol. 2012, 138(12):2051-60.